NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, April 22, 2026 (GLOBE NEWSWIRE) — Traction Uranium Corp. (CSE: TRAC) (OTC: TRCTF) (FRA: Z1K) (the “Company” or “Traction”) announces that it has filed an amended and restated offering document dated April [20], 2026 (the “Amended and Restated Offering Document”) pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the “Blanket Order”). The Amended and Restated Offering Document was filed after the Company satisfactorily addressed regulatory comments regarding the Company’s reliance on the Blanket Order. For more information about...

CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) — Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors. Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation and translational research, while Exicure will provide Burixafor and lead clinical and regulatory strategy. Burixafor successfully completed a Phase 2 clinical trial in multiple myeloma last year, providing a foundation for further...

Perth, April 23, 2026 (GLOBE NEWSWIRE) — MARCH 2026 QUARTER REPORT Perseus reports strong operational performance; cash & bullion rises to US$817 million PERTH, Western Australia/April 23, 2026/Perseus Mining Limited (“Perseus” or the “Company”) (TSX & ASX: PRU) reports on its activities for the three months’ period ended March 31, 2026 (the “Quarter”). Below is a summary of the release. The full report is available at www.perseusmining.com, www.sedarplus.ca and www.asx.com.au. OverviewQ3 FY26 production totalled 107,144 ounces of gold at an All-In Site Costs of US$1,748 per ounce Average cash margin of US$2,395/oz of gold produced, delivering notional operating cashflow of US$252 million Cash and bullion of US$817 million, plus liquid listed securities of US$254 million First gold produced from CMA Underground at...

MINNEAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) — Clearfield, Inc. (NASDAQ: CLFD), the leader in community broadband fiber connectivity, today announced that it will release results for the second quarter of fiscal 2026, ended March 31, 2025, on Wednesday, May 6, 2026, after the close of the market. The company will host a conference call at 5:00 p.m. Eastern time (4:00 p.m. Central time) to discuss its financial results with the investment community. Financial results will be available on the Investor Relations section of the company’s website along with a shareholder letter. Date: Wednesday, May 6, 2026Time: 5:00 p.m. Eastern time (4:00 p.m. Central time)U.S. dial-in: 1-844-826-3033International dial-in: 1-412-317-5185 The conference call will be webcast live and available for replay here. An audio replay of the call will be available...

Poplar Bluff, Missouri, April 22, 2026 (GLOBE NEWSWIRE) — Southern Missouri Bancorp, Inc. (“Company”) (NASDAQ: SMBC), the parent corporation of Southern Bank (“Bank”), today announced preliminary net income for the third quarter of fiscal 2026 of $17.8 million, an increase of $2.1 million, or 13.3%, as compared to the same period of the prior fiscal year. The increase was attributable to increases in net interest income and noninterest income, partially offset by increases in provision for credit losses (PCL), noninterest expense, and income tax expense. Preliminary net income was $1.60 per fully diluted common share for the third quarter of fiscal 2026, an increase of $0.21 as compared to the $1.39 per fully diluted common share reported for the same period of the prior fiscal year.    Highlights for the third quarter of fiscal...

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin disease that causes itch and hives that can be debilitating for young children, especially for those whose disease remains uncontrolled CSU marks the fifth disease driven in part by type 2 inflammation for which Dupixent is approved in children younger than 12 years of age TARRYTOWN, N.Y. and PARIS, April 22, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of children aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 antihistamine...

WILMINGTON, N.C. and SYDNEY, April 22, 2026 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), the platform for agentic banking, today announced Nick Edwards as the new Managing Director for the APAC region. Edwards is a seasoned commercial and regional leader with deep expertise across financial services. With nearly two decades of experience across the region, he has developed an intimate understanding of the unique dynamics, customer needs and market opportunities that define financial services in the Asia-Pacific region. Most recently, Edwards served as Chief Commercial Officer, APAC at FNZ Group. Prior to that, he spent more than six years at Temenos and other financial services providers in various leadership roles. “Nick brings exactly the right combination of regional expertise, commercial leadership, and a people-first...

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticariaApproval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study program CSU is a chronic skin disease that causes itch and hives that can be debilitating for young children, especially for those whose disease remains uncontrolled CSU marks the fifth disease driven in part by type 2 inflammation for which Dupixent is approved in children younger than 12 years of ageParis and Tarrytown, NY, April 22, 2026. The US Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of children aged two to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic...

Company reiterates commitment to driving a smooth transition to expand access to affordable homeownership CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) today applauds the Federal Housing Finance Agency (FHFA) and the Department of Housing and Urban Development (HUD) for moving forward the inclusion of VantageScore® 4.0 in the U.S. mortgage market to drive affordable homeownership for consumers. “We commend FHFA and HUD for their leadership, and we stand ready to help lenders and investors adopt VantageScore 4.0,” said Satyan Merchant, senior vice president and mortgage business leader at TransUnion. “This milestone supports a more competitive and innovative credit scoring ecosystem, preserves prudent risk management and expands opportunities for creditworthy borrowers to achieve homeownership.” Greater competition...